Mind the Gap: Jenny Chang on critical gaps in breast cancer research

Posted by Biome on 15th October 2013 - 1 Comment


“Breast cancer remains a significant scientific, clinical and societal challenge,” write the authors of a large collaborative effort from over 30 UK institutions to analyse critical research gaps in preventing and treating breast cancer, as published in a recent Breast Cancer Research study.

This is an ambitious body of work that covers a vast, detailed analysis of the current state of affairs in breast cancer research, as well as the direction of future research. The authors, including Suzanne Eccles from the Institute of Cancer Research, UK and Alastair Thompson from the University of Dundee, UK, conclude that improved access to clinical tissue, new in vivo and in vitro models (including genetically engineered mouse models as well as patient derived xenograft models), new clinical trial methodologies, biomarker discovery and validation, and collaborations with physical scientists and engineers are all required to overcome some of the hurdles in breast cancer research. This well-written gap analysis identifies the following ten areas as significant research gaps:

1. Specific genetic and epigenetic changes during normal breast development and breast cancer
2. Identifying lifestyle changes
3. Screening approaches
4. Molecular pathology behind breast cancer subtypes, treatment resistance, and metastases
5. Tumour heterogeneity, dormancy, de novo and acquired resistance and how to target these processes
6. Markers for therapy resistance and sensitivity
7. Modern clinical trial development
8. Multimodality imaging
9. Survivorship issues
10. Clinically relevant and annotated tissue for translational research

This gap analysis is a brave attempt at identifying critical research questions that need to be answered in the short-term, foreseeable future. Contributed to by key opinion leaders in the UK, it succinctly summarizes the present and future of breast cancer research.

It remains to be seen if significant advances will be made in these areas, though greater awareness of survivorship issues and more collaboration, especially in areas of biobanking, ought to yield significant progress. Rethinking the design of clinical trials and screening approaches are tangible next steps. However, areas of more basic research, such as overcoming resistance, dormancy, epigenetic/genetic alterations, and markers of therapy resistance/sensitivity will remain challenging over the next decade.

It is important to note that the acquisition of clinically relevant, carefully annotated tissues requires collaborative teamwork and open dialogue between surgeons, pathologists, technicians, basic scientists, and medical oncologists. The resources needed to overcome some of these hurdles are indeed sobering and demand greater collaboration amongst different disciplines in order to attain these goals.

 

More about the author(s)

Jenny Chang, Director of the Methodist Cancer Center, Methodist Hospital, Texas, USA.

Jenny Chang is Director of the Cancer Center at the Methodist Hospital, Texas, USA. She obtained her medical degree at Cambridge University, UK before completing a fellowship in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research, UK. Chang also completed a research doctorate at the University of London, UK, where she developed an interest in breast cancer, particularly in the area of prognostic and predictive markers. Her current research interests focus on the mechanisms that regulate tumour-initiating cells, developing clinical trials that target this critical tumor initiating subpopulation, and characterising the cross-talk between different pathways that lead to chemo-resistance.

Research article

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K et al.
Breast Cancer Research 2013, 15:R92

Go to article >>